65,437 trials
Hemophilia A or B With Inhibitors · Hemophilia A · Hemophilia B
Primary: Reduction in Annualized Bleeding Episode Rate (ABR) Among Participants Receiving Prophylactic Treatment as Compared to Those Treated On-demand — 28.7; 7.9 bleeds/year…
Iron Deficiency Anemia
Primary: Efficacy of 1020 mg of Ferumoxytol Over 15 Minutes. Hemoglobin Measurements Will Take Place at Four and Eight Week Visit. — 85; 58; 92; 86 percentage of participants
Schizophrenia
Primary: Maximum Concentration of Clozapine in Plasma — 524.62; 551.18 ng/mL
Sleep Apnea · Hypertension · Hyperlipidemia
Primary: Proportion of Patients With an Uneventful Creation of a Functional Staple Line — 28 participants
Cirrhosis
Primary: Body Weight (Amount of Change) — -0.68; -2.31; -1.88; -1.67 Kg — p=0.3167
Dry Eye Syndromes
Primary: Percentage of Patients in Each Category of the Dry Eye Workshop Severity (DEWS) Scale — 65.0; 29.0; 4.2; 1.8 Percentage of Patients
Major Depressive Disorder
Primary: Patients With Any Treatment Emergent Adverse Events (TEAEs) — 89 participants
Intermittent Urethral Catheterization
Primary: Overall Discomfort During Catheterization — 2.6; 2.4; 1.8 cm
Primary Myelofibrosis · MPN-associated Myelofibrosis
Primary: Percentage of Participants Who Achieved RBC-Transfusion Independence — 17.3; 16.7 percentage of participants — p=1.000
Heart Failure
Primary: All Cause Mortality — 163; 118 participants
Kidney Cancer · Leukemia · Lymphoma
Primary: Neurotoxicity as Measured by a Scored Neurologic Examination at Baseline, 5 Weeks, and 10 Weeks (if Applicable) — 26; 34 percentage of participants
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Diurnal IOP Change From Baseline at Week 8 — -6.84; -6.00 millimeters mercury (mmHg)
Pretreatment Method of Transnasal Endoscopy
Primary: Success Rate of Transnasal Endoscopy — 88; 88 percentage of Participants
Pandemic Influenza
Primary: Assess the Proportion of Subjects in Each Dose Group Achieving Seroconversion and Seroprotection for HI Antibody Titer Through Day 28. — 35.4; 47.4; 37.6; 53.1…
Diarrhea
Primary: Characterization and Comparison of the Safety of the TD Vaccine System: (1) Solicited and Unsolicited Adverse Events (AEs) (2) Clinical Laboratory Safety (3) Serious AEs…